Achillion's Phase 2 Trial Of ACH-3102, Sofosbuvir Meets Primary Objective

(RTTNews) - Achillion Pharmaceuticals, Inc. (ACHN) Saturday said it achieved the primary obejective for its ongoing Phase 2 trial evaluating ACH-3102 in combination with sofosbuvir, for genotype 1 treatment HCV.

In a late breaker poster presentation, Achillion reported that, of the 12 patients treated, 100 percent achieved the primary objective of sustained viral response 12 weeks (SVR12) after the completion of therapy.

The phase 2 open-label, randomized, partial-crossover study aimed to evaluate the efficacy, safety, and tolerability of eight weeks or six weeks of ACH-3102 and sofosbuvir in treatment-naïve genotype 1 HCV-infected patients.

In addition, the company reported updated pre-clinical results on ACH-3422. The in vitro results showed that this nucleotide pro-drug has improved potency against genotype 3 HCV, when compared with sofosbuvir.